Rituximab outperformed steroids in Graves’ ophthalmopathy

SAN JUAN, Puerto Rico — Despite data presented earlier at the American Thyroid Association Annual Meeting showing that rituximab was not effective in treating Graves’ ophthalmopathy, another presenter here said that the drug does improve disease state when compared with methylprednisolone.“Response to rituximab was as high as 93%, compared to 69% observed after IV steroid,” Mario Salvi, MD, from the University of Milan in Italy, said. “Preliminary evidence of NOSPECS class 2 signs shows improvement after rituximab.”

BLOG: Look at the big picture when worried about a light appointment book, part 1

In mid-winter and mid-summer, my office phone starts ringing in earnest. “John, you’ve got to get in here. Our volume is going through the floor.” These normal seasonal lulls in patient volume are often misinterpreted by clients as the harbinger of disaster. In a few cases, these concerns are warranted. But more often, light clinics and surgical calendars are driven by normal seasonal market forces, some of which are under administrative control. Slips in volume that you can’t control can at least be predicted and braced for in advance.